Medical/Pharmaceuticals
Jolly Good develops a medical VR filming system exclusively for ambulances with physicians
TOKYO, Dec. 21, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") developed a medical VR filming system for ambulances with physicians in collaboration with Nippon Medical School Hospital Emergency & Critical Care Medicine (Bunkyo-ku, Tokyo; Director: Shoji Yokobori). Together, they will begin t...
2021-12-21 21:00
2025
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
* The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS in both the overall population and the Asian subgroup, the median overall survival (OS) in the serplulimab and placebo groups were 15.38 and 11.10 months, respectively, reducing risk of death by 38%...
2021-12-20 22:00
3323
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company's R&D organization, focusing on global pipelin...
2021-12-20 21:00
2542
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...
2021-12-20 10:56
3447
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
TAIPEI and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...
2021-12-17 20:00
3251
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs inSingapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcar...
2021-12-16 21:00
3593
Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2021-12-16 21:00
3260
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notif...
2021-12-16 21:00
2436
Launching the world's first all-in-one medical and welfare VR platform JOLLYGOOD+
TOKYO, Dec. 16, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") will begin
providing JOLLYGOOD+, an all-in-one medical and welfare VR platform that
integrates medical education VR for medical staff training, nursing care
training VR, social skills training (SST) VR, and recreational VR.
2021-12-16 21:00
2252
Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting
TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug...
2021-12-16 20:00
2842
Bionomics Limited Announces Pricing of Initial Public Offering in the United States
ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...
2021-12-16 19:00
3332
Statement by WuXi AppTec Regarding Recent Market Fluctuation
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations...
2021-12-16 08:00
3125
SQREEM's New AI-powered Study Examines Motivations Surrounding COVID-19 Vaccine Resistance in the US
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- COVID-19 vaccines have once again become a hot topic inthe United States as President Joe Biden pushes on with vaccination mandates in a bid to manage concerns around the Omicron variant ahead of the winter flu season. Despite vaccination ratesreaching 60%...
2021-12-15 22:00
1938
FDA Breakthrough Devices Designation Application to Fast-Track Painful Finger-Prick Alternative for People Living with Diabetes
SYDNEY, Dec. 15, 2021 /PRNewswire/ -- Life Science Biosensor Diagnostics Pty Ltd (LSBD), a life sciences and medical technology company and subsidiary of The iQ Group Global, announced it has filed an application with the U.S Food and Drug Administration (FDA) for Breakthrough Devices Designation...
2021-12-15 21:01
2542
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) ofChina's Na...
2021-12-15 21:00
2097
Red Seal brings New Zealand's #1 best-selling herbal and mineral toothpaste to Pharmaca Integrative Pharmacies, USA
AUCKLAND, New Zealand, Dec. 14, 2021 /PRNewswire/ -- Wednesday 14 December, 2021
, Red Seal is proud to announce their herbal and mineral toothpastes are now
conveniently available at all 28 distinguished Pharmaca stores nationwide.
www.redseal.global/usa
2021-12-15 10:41
2307
Limbach Group adopts QuantaMatrix dRAST™ in routine clinical use
* QuantaMatrix's direct Rapid Antimicrobial Susceptibility Testing system (dRAST) improves optimal prescription of antibiotics by two days comparedto conventional methods * Following successful validation of dRAST platform in Europe at key reference laboratories, system now adopted for clinica...
2021-12-15 07:39
2284
Cochl joins ABB's innovation growth hub SynerLeap for audio-based anomaly detection and emergency monitoring
SAN JOSE, Calif., Dec. 14, 2021 /PRNewswire/ -- Cochl has become a member of Synerleap, ABB's innovation growth hub located in the heart of the ABB's Head Office in VästeråsSweden. Synerleap aims to create an ecosystem where ABB can utilize and enable technology companies to grow and expand on a ...
2021-12-15 01:00
2462
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety
SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three ...
2021-12-14 22:04
3115
ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from six st...
2021-12-14 22:04
2810
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
10935
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
6532
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
5617
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5378